The FLIGHTED preprint is out, with some exciting updates! Co-authored with Boqiang Tu, lindsey, and Kevin Esvelt. biorxiv.org/content/10.110… 1/

Our new preprint describes “CROPseq-multi”: a versatile solution for multiplexed perturbation and decoding in pooled CRISPR screens doi.org/10.1101/2024.0… Reagents on Addgene: addgene.org/browse/article…

Kicking off 2024 by sharing a preprint of my PhD work! We report an engineered cytokine therapy that elicits some of the most profound anti-tumor immunity we have seen in our labs' preclinical work.

Preprint and walk-through below:

Excited to share our preprint on metabolic differences in the vaginal #microbiome . We find key differences in fatty acid metabolism among #Lactobacillus species & leverage those findings to identify a potential new therapy for bacterial vaginosis (BV) & #WomensHealth 🧵 (1/n)

New preprint! In chronic stress, cells must balance their own survival with tissue-level roles. Prior work has emphasized stress-induced drivers of cell death, but what happens to surviving cells? How do they adapt, and how do their changes connect to long-term dysfunction? (1/n)

If last week’s thread on #singlecell foundation models for zero-shot tasks left you asking “what about fine-tuning for few-shot tasks?” -- check out our new preprint! 👇biorxiv.org/content/10.110…

ICYMI, here's the zero-shot analysis led by Kasia Kędzierska 💙💛 🙂biorxiv.org/content/10.110…

PhD student Constantine Tzouanas studies how processes involving individual cells shape whether pathogens will defeat their hosts — or vice versa. In addition to uncovering leads to new treatments, he seeks to better understand how the body works. mitsha.re/NrtX50PAm7S

We are thrilled to announce the launch of ReNAgade Therapeutics with $300M+ in Series A financing. With our comprehensive deliver, code, edit, insert technologies, we’re unlocking the limitless potential for RNA medicines. renagadetx.com/news